Fetal death resulting in stillbirth is generally acknowledged as a feature of antiphospholipid syndrome. Recently published studies appear to confirm the association between antiphospholipid antibodies (aPL) and stillbirth, though additional studies of better design would be welcome. Emerging evidence suggests that treatment with heparin agents and low dose aspirin to prevent fetal death is imperfect. New therapeutic approaches for patients with lupus anticoagulant or triple aPL positivity are needed.
de JesusGRAgmon-LevinNAndradeCA. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev2014; 13: 795–813.
SilverRMBranchDWGoldenbergRIamsJDKlebanoffMA. Nomenclature for pregnancy outcomes: time for a change. Obstet Gynecol2011; 118: 1402–1408.
4.
LawnJEBlencoweHWaiswaP. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet2016; 387: 587–603.
5.
Stillbirth Collaborative Research Network Writing Group. Causes of death among stillbirths. JAMA2011; 306: 2459–2468.
6.
SilverRMParkerCBReddyUM. Antiphospholipid antibodies in stillbirth. Obstet Gynecol2013; 122: 641–657.
7.
LockshinMDKimMLaskinCA. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum2012; 64: 2311–2318.
8.
YelnikCMLaskinCAPorterTF. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med2016; 3: e000131–e000131.
9.
BouvierSCochery-NouvellonELavigne-LissaldeG. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood2014; 123: 404–413.
10.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
11.
RuffattiATonelloMVisentinMS. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology2011; 50: 1684–1689.
12.
SciasciaSBranchDWLevyRA. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost2015; 115: 285–290.
13.
LefkouEMamopoulosADagklisTVosnakisCRoussoDGirardiG. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest2016; 126: 2933–2940.
14.
BermanJGirardiGSalmonJE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol2005; 174: 485–490.
